Antibiotic prophylaxis to prevent infections in human immunodeficiency virus (HIV)-infected post-natal wome
Not Applicable
Completed
- Conditions
- HIV/bacterial infectionsInfections and InfestationsHuman immunodeficiency virus [HIV] disease resulting in infectious and parasitic diseases
- Registration Number
- ISRCTN65670698
- Lead Sponsor
- niversity College London (UK)
- Brief Summary
2011 results in: https://www.ncbi.nlm.nih.gov/pubmed/21281407 (added 31/10/2019)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 600
Inclusion Criteria
1. Women who have recently given birth
2. Aged 16 years or more
3. HIV-seropositive at stage 2 or 3 of the World Health Organization (WHO) staging system for HIV infection
4. Evidence of residence at a permanent address in Lusaka
5. Willing to attend at two-monthly intervals for follow-up
6. Informed written or verbal consent
Exclusion Criteria
1. Current opportunistic infection or currently receiving co-trimoxazole
2. History of sulphonamide allergy
3. Breast feeding women with premature babies
4. Advanced HIV-disease or serious non-HIV disease (i.e. unlikely to survive more than 2 weeks)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br> 1. Mortality from any cause or hospital admission, measured at end of trial; all deaths will be recorded as they occur<br> 2. Safety (serious adverse events)<br>
- Secondary Outcome Measures
Name Time Method Adherence and completion rates, recorded throughout the trial.